STAMFORD, Conn., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker , M.D., chief executive officer, will present a corporate overview at three upcoming conferences.
Details of the conferences are as follows:
- Stifel 2015 Healthcare Conference, November 17, 2015 at 4:30 pm Eastern Time, Lotte New York Palace, New York, NY
- Piper Jaffray 27 th Annual Healthcare Conference, December 1, 2015 at 8:00 am Eastern Time, Lotte New York Palace, New York, NY
- Oppenheimer 26 th Annual Healthcare Conference, December 9, 2015 at 2:10 pm Eastern Time, Westin New York Grand Central, New York, NY
Live webcasts of the presentations will be available at http://ir.loxooncology.com/ .
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com .
Contacts for Loxo Oncology, Inc. Company: Jacob S. Van Naarden Vice President, Corporate Development and Strategy jake@loxooncology.com
Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 prahmer@troutgroup.com
Media: Dan Budwick Pure Communications, Inc. 973-271-6085 dan@purecommunicationsinc.com